f-Star Business Update Moves Into New Facility In Cambridge, UK
CAMBRIDGE, UK – 18 March 2016 – F-star, a biopharmaceutical company developing novel immuno-oncology bispecific antibodies, today announced the opening of its new facility in the Eddeva building on the Babraham Research Campus in Cambridge, UK. The Company also announced the appointment of Michael Davies as VP Protein Sciences.
The new facility will house F-star’s expanded team which has grown to just over 60 members of staff over the last year. F-star has successfully hired several key employees and developed its capabilities to maximise the potential of its powerful modular antibody technology for the discovery of bispecific antibody therapeutics and further progress its portfolio of novel immuno-oncology compounds into the clinic.
Mike Davies joins F-star as VP Protein Sciences from CPI Biologics where he worked as Head of Analytical Strategy, Biologics. He has over 15 years’ experience in the development, manufacture and commercialisation of recombinant protein therapeutics. He has successfully run Chemistry, Manufacturing and Control (CMC) projects to support the launch of several commercial products. Previously, he worked at Lonza where he held leadership roles in analytical strategy and development.
In January, F-star announced a collaborative discovery & development agreement with AbbVie for the development of bispecific antibodies against two immuno-oncology targets. This collaboration further leverages the strength of F-star’s technology and follows ongoing partnerships with leading biopharmaceutical companies including: Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim.
John Haurum, Chief Executive Officer of F-star, said: “At F-star we are proud to be developing the next generation of cancer therapies through our leadership in bispecific antibodies. The new facility will create an ideal environment for our staff to harness the power of our bispecific platform. We are pleased to welcome Mike to the team and look forward to working with him. His strong experience in the development and commercialisation of recombinant protein therapeutics will further enable us to progress our immuno-oncology pipeline into the clinic.”
-Ends-
For further information, please contact:
F-star
John Haurum
Chief Executive Officer
+ 44 7881 244 040
john.haurum@f-star.com
Jane Dancer
Chief Business Officer
+ 44 7739 174 297
jane.dancer@f-star.com
Hume Brophy
Mary Clark, Eva Haas, Alexia Faure
+44 207 862 6381
fstar@humebrophy.com
About F-star
F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies where the second binding site is in the constant Fc region of an antibody. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including AbbVie, Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim. The Company has built a comprehensive IP estate around its technology and product pipeline, with over 50 patent applications filed and over 25 granted patents.
F-star’s management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. F-star currently employs over 60 people at its research site in Cambridge, UK.
For more information visit www.f-star.com
The new facility will house F-star’s expanded team which has grown to just over 60 members of staff over the last year. F-star has successfully hired several key employees and developed its capabilities to maximise the potential of its powerful modular antibody technology for the discovery of bispecific antibody therapeutics and further progress its portfolio of novel immuno-oncology compounds into the clinic.
Mike Davies joins F-star as VP Protein Sciences from CPI Biologics where he worked as Head of Analytical Strategy, Biologics. He has over 15 years’ experience in the development, manufacture and commercialisation of recombinant protein therapeutics. He has successfully run Chemistry, Manufacturing and Control (CMC) projects to support the launch of several commercial products. Previously, he worked at Lonza where he held leadership roles in analytical strategy and development.
In January, F-star announced a collaborative discovery & development agreement with AbbVie for the development of bispecific antibodies against two immuno-oncology targets. This collaboration further leverages the strength of F-star’s technology and follows ongoing partnerships with leading biopharmaceutical companies including: Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim.
John Haurum, Chief Executive Officer of F-star, said: “At F-star we are proud to be developing the next generation of cancer therapies through our leadership in bispecific antibodies. The new facility will create an ideal environment for our staff to harness the power of our bispecific platform. We are pleased to welcome Mike to the team and look forward to working with him. His strong experience in the development and commercialisation of recombinant protein therapeutics will further enable us to progress our immuno-oncology pipeline into the clinic.”
-Ends-
For further information, please contact:
F-star
John Haurum
Chief Executive Officer
+ 44 7881 244 040
john.haurum@f-star.com
Jane Dancer
Chief Business Officer
+ 44 7739 174 297
jane.dancer@f-star.com
Hume Brophy
Mary Clark, Eva Haas, Alexia Faure
+44 207 862 6381
fstar@humebrophy.com
About F-star
F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies where the second binding site is in the constant Fc region of an antibody. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including AbbVie, Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim. The Company has built a comprehensive IP estate around its technology and product pipeline, with over 50 patent applications filed and over 25 granted patents.
F-star’s management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. F-star currently employs over 60 people at its research site in Cambridge, UK.
For more information visit www.f-star.com